Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	4,499	2,014	1,302	2,568	738	896
Market Cap Growth	110.40%	54.68%	-49.31%	247.92%	-17.65%	41.33%
Enterprise Value	3,511	1,306	777.64	2,227	551.2	629.46
Last Close Price	54.65	27.82	23.35	54.80	21.15	25.80
PE Ratio	-	-7.42	-8.08	-19.09	-7.32	-10.24
PB Ratio	4.57	2.68	2.43	7.86	4.36	3.46
P/TBV Ratio	4.47	2.49	2.29	6.54	4.36	3.14
P/FCF Ratio	-	-8.75	-8.96	-27.76	-9.26	-12.63
P/OCF Ratio	-	-8.75	-8.96	-27.76	-9.26	-12.66
EV/EBITDA Ratio	-	-4.39	-4.28	-19.42	-5.54	-7.88
EV/EBIT Ratio	-	-4.58	-4.50	-19.34	-5.46	-7.85
EV/FCF Ratio	-	-5.68	-5.35	-24.08	-6.92	-8.87
Debt / Equity Ratio	0.00	0.05	0.05	0.03	0.01	0.01
Debt / EBITDA Ratio	0.00	-0.12	-0.14	-0.09	-0.01	-0.02
Debt / FCF Ratio	0.00	-0.16	-0.18	-0.11	-0.02	-0.02
Quick Ratio	15.48	18.69	28.75	18.42	7.49	20.47
Current Ratio	15.83	19.38	29.27	18.61	7.70	20.70
Return on Equity (ROE)	-34.29%	-39.22%	-35.22%	-45.20%	-47.11%	-40.89%
Return on Assets (ROA)	-36.04%	-40.60%	-36.90%	-41.71%	-43.03%	-38.96%
Return on Invested Capital (ROIC)	-215.31%	-752.95%	-1592.83%	-6848.41%	-5095.25%	-7770.63%
Return on Capital Employed (ROCE)	-37.84%	-42.37%	-38.47%	-45.35%	-46.85%	-41.21%
Earnings Yield	-6.51%	-13.48%	-12.38%	-5.24%	-13.66%	-9.77%
FCF Yield	-5.56%	-11.43%	-11.17%	-3.60%	-10.79%	-7.92%
Buyback Yield / Dilution	-23.38%	-27.71%	-34.84%	-11.94%	-10.69%	-108.77%
Total Shareholder Return	-23.38%	-27.71%	-34.84%	-11.94%	-10.69%	-108.77%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q